CD27: A Potential Drug Target and Biomarker for T Cell Activation
CD27: A Potential Drug Target and Biomarker for T Cell Activation
Abstract:
CD27 is a cell surface antigen that is expressed in various tissues and cell types, including T cells. It is a key molecule in the regulation of T cell activation and proliferation. CD27 has been identified as a potential drug target and biomarker for T cell- related diseases. This article will discuss the biology of CD27, its potential as a drug target, and its use as a biomarker for tracking disease progression.
Introduction:
T cells are a vital part of the immune system, responsible for protecting the body against infection and disease. T cells are activated when their recognition of foreign antigens is successful. CD27 is a cell surface antigen that is expressed in various tissues and cell types, including T cells. It is a key molecule in the regulation of T cell activation and proliferation.
CD27: Structure and Function
CD27 is a 21-kDa protein that is expressed in various tissues and cell types, including T cells, B cells, and natural killer cells. It is composed of a variable region (V尾) and a constant region (C尾). The V尾 region consists of two constant frameworks, alpha-2 and alpha-3, while the C尾 region consists of a variable region (V尾1) and a variable region (V尾2). CD27 has been shown to play a role in the regulation of T cell activation and proliferation.
CD27 is involved in the T cell receptor (TCR) signaling pathway. TCR is a transmembrane protein that consists of a variable region and a constant region. The TCR is responsible for recognizing foreign antigens and for regulating T cell activation and proliferation. CD27 is located in the extracellular domain of the TCR and is in close proximity to the TCR. It is thought to interact with the TCR and play a role in the regulation of T cell activation and proliferation.
CD27 has also been shown to play a role in the regulation of T cell death. T cells are natural death cells, and their death is regulated by various factors, including CD27. Studies have shown that CD27 is involved in the regulation of T cell death via the production of death factor-1 (DF1) and the inhibition of programmed cell death (PD-1).
CD27 as a Drug Target
CD27 has been identified as a potential drug target for T cell-related diseases. The development of CD27-targeted therapies has the potential to treat a variety of T cell-related diseases, including autoimmune diseases, cancer, and infections.
One approach to targeting CD27 is to use antibodies that specifically recognize and bind to CD27. These antibodies can be used to block the activity of CD27 and prevent it from interacting with the TCR and other molecules involved in T cell activation and proliferation. This approach has has been shown to be effective in animal models of T cell-related diseases.
Another approach to targeting CD27 is to use small molecules that inhibit the activity of CD27. These molecules can be used to inhibit the production of DF1 and PD-1, and prevent CD27 from interacting with the TCR and other molecules involved in T cell activation and proliferation.
CD27 as a Biomarker
CD27 has also been used as a biomarker for tracking disease progression in T cell-related diseases. The levels of CD27 have been shown to be elevated in various tissues and cell types, including T cells, B cells, and natural killer cells, in individuals with certain T cell-related diseases. This increase in CD27 levels can be used as a biomarker for tracking disease progression and evaluating the effectiveness of therapies.
Conclusion:
In conclusion, CD27 is a cell surface antigen that is expressed in various tissues and cell types, including T cells. It is involved in the regulation of T cell activation and proliferation and has been identified as a potential drug target and biomarker for T cell- related diseases. Further research is needed to fully understand the role of CD27 in T cell biology and its potential as a drug target and biomarker.
Protein Name: CD27 Molecule
Functions: Receptor for CD70/CD27L. May play a role in survival of activated T-cells. May play a role in apoptosis through association with SIVA1
The "CD27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD27 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5
